Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT04493853

PHASE3

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the combination of capivasertib plus abiraterone (+prednisone/prednisolone) plus ADT is superior to placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC characterised by PTEN deficiency with respect to radiographic progression-free survival (rPFS) per 1) Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for soft tissue and/or Prostate Cancer Working Group (PCWG3) for bone as assessed by the investigator 2) death due to any cause.

Official title: A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.

Key Details

Gender

MALE

Age Range

18 Years - 130 Years

Study Type

INTERVENTIONAL

Enrollment

1012

Start Date

2020-07-13

Completion Date

2027-03-29

Last Updated

2026-04-01

Healthy Volunteers

Conditions

Hormone-Sensitive Prostate Cancer

Interventions

DRUG

Capivasertib

400 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

OTHER

Placebo

matched to capivasertib appearance (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

DRUG

Abiraterone Acetate

Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.

Inclusion Criteria: * Asymptomatic or mildly symptomatic, histologically-confirmed de novo hormone-sensitive prostate adenocarcinoma without small-cell tumours diagnosed within 180 days of randomisation * Consent to provide a FFPE tissue block (preferred) or slides. Tissue from bone metastases is not acceptable * A valid PTEN IHC result indicating PTEN deficiency (centralized testing) * Metastatic disease documented prior to randomisation by clear evidence of ≥ 1 bone lesion and/or ≥ 1 soft tissue lesion accurately assessed at baseline and suitable for repeated assessment with CT and/or MRI. PSMA PET identification only will not be eligible * Candidate for abiraterone and steroid therapy * Ongoing ADT with GnRH analogue, or LHRH agonists or antagonist, or bilateral orchiectomy (regardless of method) is from 0 days to a max. of 93 days prior to randomisation * Eastern Cooperative Oncology Group (ECOG)/WHO performance status 0 to 1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks * Able and willing to swallow and retain oral medication * 7-day Brief Pain Inventory-Short Form (BPI-SF) and Brief Fatigue Inventory(BFI) questionnaires and the analgesic diary during screening completed. Participants must complete a minimum of 4 successful assessments within a 7-day period prior to randomisation. * Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm * Capable of giving signed informed consent * Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of samples Exclusion Criteria: * Prior radical prostatectomy or definitive radiotherapy with therapeutic intent for prostate cancer. Palliative radiotherapy is allowed providing any wide field radiation therapy is completed more than 4 weeks before the start of study treatment * Major surgery (excluding placement of vascular access, transurethral resection of prostate, bilateral orchiectomy, or internal stents) within 4 weeks of the start of study treatment * Brain metastases, or spinal cord compression (unless spinal cord compression is asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment) * Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease * Any of the following cardiac criteria: i. Mean resting corrected QT interval (QTc) \> 470 msec obtained from triplicate ECGs ii. History of QT prolongation associated with other medications that required discontinuation of that medication. iii. Family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives. iv. Medical history significant for arrhythmia which is symptomatic or requires treatment, symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. v. Any clinically important abnormalities in conduction or morphology of resting ECG (eg, complete left bundle branch block, third-degree heart block) vi. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as hypokalaemia, potential for torsades de pointes, congenital long QT syndrome, or any concomitant medication known to significantly prolong the QT interval vii. Experience of any of the following procedures or conditions in the preceding 3 months: coronary artery bypass graft, angioplasty, myocardial infarction, angina pectoris. viii. Congestive heart failure NYHA Grade ≥ 2 ix. Symptomatic hypotension - systolic blood pressure (SBP) \<90 mmHg and/or diastolic blood pressure (DBP) \<50 mmHg x. Uncontrolled hypertension (SBP ≥ 160 mmHg or DBP ≥ 95 mmHg). * Clinically significant abnormalities of glucose metabolism as defined by any of the following: i. Patients with diabetes mellitus type 1 or diabetes mellitus type 2 requiring insulin treatment ii. HbA1c ≥8.0% (63.9 mmol/mol) * Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: i. Absolute neutrophil count \< 1.5x 10\^9/L ii. Platelet count \< 100x 10\^9/L iii. Haemoglobin \< 9 g/dL (\< 5.59 mmol/L) iv. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \> 2.5x upper limit of normal (ULN) if no demonstrable liver metastases or \> 5x ULN in the presence of liver metastases. Elevated alkaline phosphatase (ALP) is not exclusionary if due to the presence of bone metastases and liver function is otherwise considered adequate in the investigator's judgement v. Total bilirubin \> 1.5x ULN (participants with confirmed Gilbert's syndrome may be included in the study with a higher value) vi. Creatinine clearance \< 50 mL/min (measured or calculated by Cockcroft and Gault equation) * As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or known active infection including hepatitis B, hepatitis C, and HIV * unevaluable for both bone and soft tissue progression as defined by meeting both of the following criteria: i. a "superscan" of bone scan, and ii. no soft tissue lesion that can be assessed by RECIST criteria * Refractory nausea and vomiting, malabsorption syndrome, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection, or other condition that would preclude adequate absorption of capivasertib * Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent * Evidence of dementia, altered mental status, or any psychiatric condition that would prohibit understanding or rendering of informed consent * Previous allogeneic bone marrow transplant or solid organ transplant * History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease. * Treatment with any of the following: i. Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment ii. Any investigational agents or study drugs from a previous clinical study within 30 days or 5 half-lives (whichever is longer) of the first dose of study treatment iii. Any other chemotherapy, immunotherapy, immunosuppressant medication (other than corticosteroids) or anticancer agents within 3 weeks of the first dose of study treatment. A longer washout may be required for drugs with a long half-life (eg, biologics) iv. Strong inhibitors or strong inducers of CYP3A4 within 2 weeks before the start of study treatment (3 weeks for St John's wort). Note that adequate washout or dose reduction may be required for some CYP3A substrates prior to initiating Capivasertib dosing. * Drugs known to significantly prolong the QT interval and associated with Torsades de Pointes within 5 half-lives of the first dose of study treatment * Participation in another clinical study with an investigational product administered in the last 30 days or 5 half-lives, whichever is longer. * History of hypersensitivity to active or inactive excipients of capivasertib, abiraterone, or drugs with a similar chemical structure or class. * Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). * Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements. * Any restriction or contraindication based on the local prescribing information that would prohibit the use of abiraterone.

Locations (323)

Research Site

Tucson, Arizona, United States

Research Site

Tucson, Arizona, United States

Research Site

La Jolla, California, United States

Research Site

Orange, California, United States

Research Site

San Diego, California, United States

Research Site

Denver, Colorado, United States

Research Site

Lakewood, Colorado, United States

Research Site

Norwich, Connecticut, United States

Research Site

Fort Myers, Florida, United States

Research Site

West Palm Beach, Florida, United States

Research Site

Chicago, Illinois, United States

Research Site

Geneva, Illinois, United States

Research Site

Lisle, Illinois, United States

Research Site

Baltimore, Maryland, United States

Research Site

Detroit, Michigan, United States

Research Site

Grand Rapids, Michigan, United States

Research Site

Troy, Michigan, United States

Research Site

Syracuse, New York, United States

Research Site

The Bronx, New York, United States

Research Site

Asheville, North Carolina, United States

Research Site

Durham, North Carolina, United States

Research Site

Columbus, Ohio, United States

Research Site

Lancaster, Pennsylvania, United States

Research Site

Philadelphia, Pennsylvania, United States

Research Site

Pittsburgh, Pennsylvania, United States

Research Site

Charleston, South Carolina, United States

Research Site

Myrtle Beach, South Carolina, United States

Research Site

Chattanooga, Tennessee, United States

Research Site

Houston, Texas, United States

Research Site

Norfolk, Virginia, United States

Research Site

Roanoke, Virginia, United States

Research Site

Seattle, Washington, United States

Research Site

Madison, Wisconsin, United States

Research Site

Berazategui, Argentina

Research Site

Buenos Aires, Argentina

Research Site

CABA, Argentina

Research Site

CABA, Argentina

Research Site

Ciudad de Buenos Aires, Argentina

Research Site

Ciudad de Buenos Aires, Argentina

Research Site

La Plata, Argentina

Research Site

Mendoza, Argentina

Research Site

Rosario, Argentina

Research Site

San Salvador de Jujuy, Argentina

Research Site

Birtinya, Australia

Research Site

Darlinghurst, Australia

Research Site

Kingswood, Australia

Research Site

Orange, Australia

Research Site

South Brisbane, Australia

Research Site

Graz, Austria

Research Site

Linz, Austria

Research Site

Salzburg, Austria

Research Site

Anderlecht, Belgium

Research Site

Ghent, Belgium

Research Site

Kortrijk, Belgium

Research Site

Liège, Belgium

Research Site

Belém, Brazil

Research Site

Belo Horizonte, Brazil

Research Site

Florianópolis, Brazil

Research Site

Fortaleza, Brazil

Research Site

Jaú, Brazil

Research Site

Joinville, Brazil

Research Site

Porto Alegre, Brazil

Research Site

Porto Alegre, Brazil

Research Site

Porto Alegre, Brazil

Research Site

Ribeirão Preto, Brazil

Research Site

Rio de Janeiro, Brazil

Research Site

Santa Maria, Brazil

Research Site

São José do Rio Preto, Brazil

Research Site

São Paulo, Brazil

Research Site

Três Lagoas, Brazil

Research Site

Pleven, Bulgaria

Research Site

Plovdiv, Bulgaria

Research Site

Plovdiv, Bulgaria

Research Site

Sofia, Bulgaria

Research Site

Sofia, Bulgaria

Research Site

Sofia, Bulgaria

Research Site

Sofia, Bulgaria

Research Site

Varna, Bulgaria

Research Site

Calgary, Alberta, Canada

Research Site

Edmonton, Alberta, Canada

Research Site

Kelowna, British Columbia, Canada

Research Site

Vancouver, British Columbia, Canada

Research Site

Brampton, Ontario, Canada

Research Site

Oshawa, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Montreal, Canada

Research Site

Santiago, Chile

Research Site

Santiago, Chile

Research Site

Santiago, Chile

Research Site

Temuco, Chile

Research Site

Viña del Mar, Chile

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Changchun, China

Research Site

Changsha, China

Research Site

Changsha, China

Research Site

Chengdu, China

Research Site

Chengdu, China

Research Site

Chongqing, China

Research Site

Chongqing, China

Research Site

Fuzhou, China

Research Site

Fuzhou, China

Research Site

Guangzhou, China

Research Site

Guangzhou, China

Research Site

Guangzhou, China

Research Site

Guiyang, China

Research Site

Hangzhou, China

Research Site

Hangzhou, China

Research Site

Hangzhou, China

Research Site

Kunming, China

Research Site

Nanchang, China

Research Site

Nanjing, China

Research Site

Nanjing, China

Research Site

Nantong, China

Research Site

Ningbo, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shengyang, China

Research Site

Tianjin, China

Research Site

Wenzhou, China

Research Site

Wuhan, China

Research Site

Xi'an, China

Research Site

Yantai, China

Research Site

Zhengzhou, China

Research Site

Zhengzhou, China

Research Site

Brno, Czechia

Research Site

Hořovice, Czechia

Research Site

Hradec Králové, Czechia

Research Site

Prague, Czechia

Research Site

Prague, Czechia

Research Site

Prague, Czechia

Research Site

Besançon, France

Research Site

Bordeaux, France

Research Site

Marseille, France

Research Site

Montpellier, France

Research Site

Nice, France

Research Site

Paris, France

Research Site

Pierre-Bénite, France

Research Site

Quimper, France

Research Site

Rennes, France

Research Site

Strasbourg, France

Research Site

Suresnes, France

Research Site

Villejuif, France

Research Site

Berlin, Germany

Research Site

Duisburg, Germany

Research Site

Hamburg, Germany

Research Site

Herne, Germany

Research Site

Mettmann, Germany

Research Site

Münster, Germany

Research Site

Nuremberg, Germany

Research Site

Nürtingen, Germany

Research Site

Wesel, Germany

Research Site

Hong Kong, Hong Kong

Research Site

Hong Kong, Hong Kong

Research Site

Lai Chi Kok, Hong Kong

Research Site

Ahmedabad, India

Research Site

Bangalore, India

Research Site

Bangalore, India

Research Site

Delhi, India

Research Site

Faridabad, India

Research Site

Kanpur, India

Research Site

Kolkata, India

Research Site

Madurai, India

Research Site

Manipal, India

Research Site

Meerut, India

Research Site

Mohali, India

Research Site

Nagpur, India

Research Site

New Delhi, India

Research Site

New Delhi, India

Research Site

Thiruvananthapuram, India

Research Site

Varanasi, India

Research Site

Haifa, Israel

Research Site

Jerusalem, Israel

Research Site

Kfar Saba, Israel

Research Site

Petah Tikva, Israel

Research Site

Ramat Gan, Israel

Research Site

Ẕerifin, Israel

Research Site

Bunkyō City, Japan

Research Site

Chiba, Japan

Research Site

Chūōku, Japan

Research Site

Fukuoka, Japan

Research Site

Hamamatsu, Japan

Research Site

Hirakata-shi, Japan

Research Site

Hirosaki-shi, Japan

Research Site

Isehara-shi, Japan

Research Site

Kanazawa, Japan

Research Site

Kashihara-shi, Japan

Research Site

Kawagoe-shi, Japan

Research Site

Kisarazu-shi, Japan

Research Site

Kita-gun, Japan

Research Site

Kobe, Japan

Research Site

Kumamoto, Japan

Research Site

Kyoto, Japan

Research Site

Miyazaki, Japan

Research Site

Morioka, Japan

Research Site

Nagano, Japan

Research Site

Nagasaki, Japan

Research Site

Nagoya, Japan

Research Site

Nagoya, Japan

Research Site

Natori-shi, Japan

Research Site

Osaka, Japan

Research Site

Osakasayama-shi, Japan

Research Site

Ota Shi, Japan

Research Site

Sagamihara-shi, Japan

Research Site

Sapporo, Japan

Research Site

Shinjuku-ku, Japan

Research Site

Toon-shi, Japan

Research Site

Tsu, Japan

Research Site

Ube-shi, Japan

Research Site

Yokohama, Japan

Research Site

Yokosuka-shi, Japan

Research Site

Yufu-shi, Japan

Research Site

Culiacán, Mexico

Research Site

Culiacán, Mexico

Research Site

Guadalajara, Mexico

Research Site

Mexico City, Mexico

Research Site

Monterrey, Mexico

Research Site

Monterrey, Mexico

Research Site

Amsterdam, Netherlands

Research Site

Hilversum, Netherlands

Research Site

Roosendaal, Netherlands

Research Site

The Hague, Netherlands

Research Site

Tilburg, Netherlands

Research Site

Utrecht, Netherlands

Research Site

Callao, Peru

Research Site

Lima, Peru

Research Site

Lima, Peru

Research Site

Lima, Peru

Research Site

Lima, Peru

Research Site

Lima, Peru

Research Site

San Isidro, Peru

Research Site

Baguio City, Philippines

Research Site

Cebu City, Philippines

Research Site

Davao City, Philippines

Research Site

Iloilo City, Philippines

Research Site

Quezon City, Philippines

Research Site

Quezon City, Philippines

Research Site

San Juan City, Philippines

Research Site

Bydgoszcz, Poland

Research Site

Gdansk, Poland

Research Site

Koszalin, Poland

Research Site

Lodz, Poland

Research Site

Olsztyn, Poland

Research Site

Poznan, Poland

Research Site

Rzeszów, Poland

Research Site

Torun, Poland

Research Site

Warsaw, Poland

Research Site

Warsaw, Poland

Research Site

Moscow, Russia

Research Site

Moscow, Russia

Research Site

Moscow, Russia

Research Site

Novisibirsk, Russia

Research Site

Novosibirsk, Russia

Research Site

Saint Petersburg, Russia

Research Site

Saint Petersburg, Russia

Research Site

Yaroslavl, Russia

Research Site

Bratislava, Slovakia

Research Site

Bratislava, Slovakia

Research Site

Martin, Slovakia

Research Site

Nitra, Slovakia

Research Site

Prešov, Slovakia

Research Site

Šaľa, Slovakia

Research Site

Trenčín, Slovakia

Research Site

Cape Town, South Africa

Research Site

Johannesburg, South Africa

Research Site

Johannesburg, South Africa

Research Site

Parow, South Africa

Research Site

Port Elizabeth, South Africa

Research Site

Pretoria, South Africa

Research Site

Daegu, South Korea

Research Site

Goyang-si, South Korea

Research Site

Seongnam-si, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Badalona (Barcelona), Spain

Research Site

Barcelona, Spain

Research Site

Las Palmas de Gran Canaria, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Oviedo, Spain

Research Site

Santander, Spain

Research Site

Seville, Spain

Research Site

Kaohsiung City, Taiwan

Research Site

Kaohsiung City, Taiwan

Research Site

Taichung, Taiwan

Research Site

Taichung, Taiwan

Research Site

Tainan, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taoyuan, Taiwan

Research Site

Bangkok, Thailand

Research Site

Bangkok, Thailand

Research Site

Bangkok, Thailand

Research Site

Chiang Mai, Thailand

Research Site

Hat Yai, Thailand

Research Site

Lampang, Thailand

Research Site

Muang, Thailand

Research Site

Ankara, Turkey (Türkiye)

Research Site

Ankara, Turkey (Türkiye)

Research Site

Antalya, Turkey (Türkiye)

Research Site

Eskişehir, Turkey (Türkiye)

Research Site

Istanbul, Turkey (Türkiye)

Research Site

Izmir, Turkey (Türkiye)

Research Site

Izmir, Turkey (Türkiye)

Research Site

Kayseri, Turkey (Türkiye)

Research Site

Cambridge, United Kingdom

Research Site

Guildford, United Kingdom

Research Site

Manchester, United Kingdom

Research Site

Plymouth, United Kingdom

Research Site

Sutton, United Kingdom

Research Site

Whitchurch, United Kingdom

Research Site

Hanoi, Vietnam

Research Site

Hà Nội, Vietnam

Research Site

Ho Chi Minh City, Vietnam

Clinical Research Directory

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (323)